Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J

Executive Summary

Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.

Advertisement

Related Content

In Brief: GSK, Bristol/Pfizer See Approvals, Baxter Holds Its Own in Hemophilia
Deal Watch: Allergan Makes Another Defensive Play Against Valeant Takeover
FDA Draws Regulatory Line Between Moxduo, HIV Combos
MorphoSys Foresees 10 New Program Starts In 2014, Earnings Deficit
MorphoSys: Accelerating The Long Transformation
Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel